Furamag capsules 25 mg. №30


Manufacturer: Latvia

urogenital infections: acute and chronic cystitis, pyelonephritis, urethritis, prostatitis; gynecological infections; for prophylactic purposes during urological operations, cystoscopy, and catheterization.



Furamag 25mg Storage
active substance: soluble furagin;

1 capsule contains soluble furagin 25 mg;

Excipients: magnesium hydroxycarbonate, potassium carbonate, talc, capsule: titanium dioxide (E 171), iron oxide yellow dye (E 172), gelatin.

Furamag 25mg Dosage form

Main physical and chemical properties: hard gelatin capsules № 4 (color brownish-yellow / brownish-yellow), which contain powder from orange-brown to red-brown color. The presence of particles of white, yellow, orange and orange-brown color is allowed.

Furamag 25mg Pharmacotherapeutic group
Antimicrobials for systemic use. Nitrofuran derivatives. ATX code J01X E.

Pharmacological properties


Furamag® is a complex compound of soluble furagin and magnesium hydroxycarbonate in a ratio of 1: 1, which has fundamentally different pharmacological properties than simple furagin (after taking the drug in an acidic stomach does not convert soluble furagin to poorly soluble furagin 3, so bioavailability® times higher than ordinary furagin).

The drug has a broad antibacterial spectrum of action against gram-positive and gram-negative microorganisms. Furamag® is effective against gram-positive cocci (streptococci and staphylococci), gram-negative rods (Escherichia coli, Salmonella, Shigella, Proteus, Klebsiella, Enterobacteria), protozoa (Giardia). Furamag® in comparison with other nitrofurans shows higher activity against staphylococci, Escherichia coli, Aerobacter aerogenes, Bact. Citrovorum, Proteus mirabilis, Proteus morganii. Furamag® is also more effective against Enterococcus faecalis, Staphylococcus spp. compared with other groups of antimicrobial drugs.


After taking Furamagu® capsules in the acidic environment of the stomach there is no conversion of furagin soluble into furagin, which significantly increases the bacteriostatic and bactericidal effect. After absorption from the digestive tract (mainly from the small intestine by passive diffusion) into the portal vein of the liver, a bacteriostatic concentration of the drug is formed.

Absorption of nitrofurans from the distal segment of the small intestine exceeds the absorption from the proximal and middle segments by 2 and 4 times, respectively. Nitrofurans are poorly absorbed in the colon.

Clinically important high content of active substance in the lymph (delays the spread of infection through the lymphatic system). In bile, the concentration of the drug is several times higher than in serum, and in cerebrospinal fluid – several times lower than in serum. In saliva, the content of soluble furagin is 30% of its concentration in the serum. The concentration of soluble furagin in the blood and tissues is relatively low, which is due to its rapid excretion, and the concentration in the urine is much higher than in the blood. The maximum concentration in the blood is maintained from 3 to 8 hours, in the urine is detected in 3-4 hours after taking the drug. Excretion of furagin soluble by the kidneys occurs by glomerular filtration and tubular secretion (85%), partially reabsorbed in the tubules, to a lesser extent biotransformation (less than 10%), which occurs in the liver and kidneys. In the case of decreased excretory function of the kidneys, the intensity of metabolism increases. At low concentrations of soluble furagin in urine the process of filtration and secretion prevails, at high concentrations secretion decreases and reabsorption increases.

Hypersensitivity to furagin, derivatives of the nitrofuran group or to excipients;
severe renal insufficiency (creatinine clearance less than 30 ml / min);
severe liver failure;
polyneuropathy (including diabetic);
glucose-6-phosphate dehydrogenase deficiency (risk of hemolysis);
porphyria (diseases caused by metabolic disorders of hemoglobin);
conducting hemodialysis or peritoneal hemodialysis.